StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Baird on Intellia Therapeutics (NTLA): 'we anticipate enthusiasm will wane'
June 24, 2024 9:49 AM
Baird analyst Jack Allen reiterated a Neutral rating and $24.00 price target on Intellia Therapeutics (NASDAQ: NTLA).The analyst comments "No ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
Brookline Capital Markets Reiterates Buy Rating on Intellia Therapeutics (NTLA)
June 26, 2024 5:27 AM
Stifel on Intellia Therapeutics (NTLA): 'Positive Ph.3 HELIOS-B data this morning validates the NTLA-2001 approach'
June 24, 2024 12:15 PM
Alnylam (ALNY) data is positive for Ionis (IONS), Intellia (NTLA) and negative for BridgeBio (BBIO) - analyst
June 24, 2024 7:58 AM
Form 4 Intellia Therapeutics, For: Jun 17 Filed by: Verwiel Frank
June 20, 2024 5:01 PM
